Targeting of HBP1/TIMP3 axis as a novel strategy against breast cancer

Malignant proliferation and metastasis are the main causes of breast cancer death. The transcription factor high mobility group (HMG) box-containing protein 1 (HBP1) is an important tumor suppressor whose deletion or mutation is closely related to the appearance of tumors. Here, we investigated the role of HBP1 in breast cancer suppression. HBP1 enhances the activity of the tissue inhibitors of metalloproteinases 3 (TIMP3) promoter, thereby increasing protein and mRNA levels of TIMP3. TIMP3 increases the phosphatase and tensin homolog (PTEN) protein level by inhibiting its degradation and acts as a metalloproteinase inhibitor to inhibit the protein levels of MMP2/9. In this study, we demonstrated that the HBP1/TIMP3 axis plays a crucial role in inhibiting the tumorigenesis of breast cancer. HBP1 deletion interferes with the regulation of the axis and induces the occurrence and malignant progression of breast cancer. In addition, the HBP1/TIMP3 axis promotes the sensitivity of breast cancer to radiation therapy and hormone therapy. Our study opens new perspectives on the treatment and prognosis of breast cancer.

 

Comments:

That's an intriguing study! It seems to highlight the significance of the HBP1/TIMP3 axis in breast cancer suppression. By elucidating the role of HBP1 in enhancing TIMP3 promoter activity, the study underscores its impact on inhibiting tumor development and progression in breast cancer.

The cascading effects on PTEN protein levels and the inhibition of MMP2/9 by TIMP3 demonstrate how this axis can influence multiple pathways implicated in cancer. Moreover, the findings suggesting increased sensitivity to radiation and hormone therapies due to the HBP1/TIMP3 axis could have substantial implications for treatment strategies.

This research potentially offers new avenues for therapeutic interventions and prognostic assessments in breast cancer. Understanding the interplay of these molecules and their impact on tumor suppression and treatment response might pave the way for more targeted and effective therapies in the future.

Related Products

Cat.No.	Product Name	Information
E1022	7,12-Dimethylbenz[a]anthracene (DMBA)	7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor as well as a potent organ-specific carcinogen.

Related Targets

Others